Cartalax CART
Bioregulator tripeptide
Synthetic bioregulator tripeptide Ala-Glu-Asp from the Khavinson programme, studied in cultured fibroblast, kidney and stem cells for ageing markers.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Bioregulator tripeptide
- Category
- Bioregulator Peptides
- Type
- Single compound
- Abbreviation
- CART
- Development and regulatory status
- Not approved by FDA or EMA, research-only bioregulator peptide
What researchers study
Synthetic tripeptide Ala-Glu-Asp (AED) from the Khavinson programme, described as a cartilage and connective-tissue peptide. Reported to alter proliferation, apoptosis and ageing-marker expression in cultured fibroblasts, kidney and stem cells, mostly in work from one research network.
Research areas
- Skin fibroblast ageing and matrix remodelling in culture
- Kidney cell ageing markers in culture
- Stem-cell gene expression during replicative ageing
- Cartilage and bone metabolism (patent claims)
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
In ageing human skin fibroblasts, AED increased sirtuin-1, sirtuin-6 and collagen I synthesis
- cell culture
AED inhibited MMP-9 synthesis, raised Ki-67 and suppressed caspase-dependent apoptosis in ageing skin fibroblast cultures
- evidence note
Cartilage-specific evidence found was limited to patent claims, with no peer-reviewed cartilage study retrieved
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
